Statistics

Total Visits

Views
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months34

Select a period of time:

Number of views in the range

Views
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months18

Views

Views
October 20240
November 20240
December 20240
January 20251
February 20252
March 202515
April 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
United States2
Germany1
 

Top cities views

Views